Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?
Over 80% of CRS with Nasal Polyps’ Patients have Type 2 Inflammation Dupixent is the first and only biologic to inhibit il-4 and il-13 signaling in crs with nasal polyps.
![](/.imaging/webp/sanofi-templates/w1080-16-9/dam/campus-sanofi-bh/campus-sanofi-bh-new/science/Images/image---2023-09-21T203833.646.png/jcr:content/image%20-%202023-09-21T203833.646.png)
Related articles
MAT-KW-2400275/V1/MAY2024